Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TMZ+ABX Chemotherapy for Recurrent Glioblastoma
ChiCTR2500106675Phase 2Not yet recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Jul 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temozolomide and paclitaxel albumin-bound in glioblastoma (GBM), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Overall survival time. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
temozolomidepaclitaxel albumin-bound
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ChiCTR2500106675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106675.